BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 16226710)

  • 1. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction via the stem cell factor receptor/c-Kit.
    Rönnstrand L
    Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Ali S; Ali S
    Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal and oncogenic forms of the receptor tyrosine kinase kit.
    Lennartsson J; Jelacic T; Linnekin D; Shivakrupa R
    Stem Cells; 2005; 23(1):16-43. PubMed ID: 15625120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
    Samayawardhena LA; Hu J; Stein PL; Craig AW
    Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kit as a human oncogenic tyrosine kinase.
    Kitamura Y; Hirotab S
    Cell Mol Life Sci; 2004 Dec; 61(23):2924-31. PubMed ID: 15583854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process.
    Zou J; Wang YD; Ma FX; Xiang ML; Shi B; Wei YQ; Yang SY
    Proteins; 2008 Jul; 72(1):323-32. PubMed ID: 18214972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
    Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT and mastocytosis.
    Lim KH; Pardanani A; Tefferi A
    Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
    Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
    Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
    Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
    Tuveson DA; Willis NA; Jacks T; Griffin JD; Singer S; Fletcher CD; Fletcher JA; Demetri GD
    Oncogene; 2001 Aug; 20(36):5054-8. PubMed ID: 11526490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-function analyses of the kit receptor for the steel factor.
    Blechman JM; Lev S; Givol D; Yarden Y
    Stem Cells; 1993 Jul; 11 Suppl 2():12-21. PubMed ID: 7691317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.
    Blume-Jensen P; Jiang G; Hyman R; Lee KF; O'Gorman S; Hunter T
    Nat Genet; 2000 Feb; 24(2):157-62. PubMed ID: 10655061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.